From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Cardiology>
  4. Summary and Comment

Reducing Nephrotoxicity with Iso-Osmolar Contrast

Iodixanol could be part of the solution for high-risk patients who undergo coronary angiography.

Nephropathy, a serious complication of contrast angiography, is common in diabetes patients with preexisting renal impairment. In this double-blind, multicenter, European trial, 129 diabetes patients with a stable serum creatinine level (≥1.5 mg/dL in men, ≥1.3 mg/dL in women, ≤3.5 mg/dL in both) were randomized to iohexol or iodixanol before coronary (126) or aortofemoral (3) angiography. Iohexol is a nonionic, monomeric contrast medium with relatively low osmolarity (780 mOsm/kg water); iodixanol is a nonionic, dimeric contrast medium that is iso-osmolar to blood (290 mOsm/kg water). The study was supported by a company that makes both agents.

The iodixanol and iohexol groups had similar baseline characteristics, including mean serum creatinine level (about 1.5-1.6 mg/dL), creatinine clearance (about 50 mL/min), and contrast volume received (about 162 mL). All patients also received about 1 L of intravenous hydration.

Three days after angiography, the mean increase in peak serum creatinine level was lower in iodixanol recipients than in iohexol recipients (0.13 vs. 0.55 mg/dL, P=0.001). A ≥0.5-mg/dL increase in creatinine level occurred in 3% and 26%, respectively (P=0.002). The odds of nephropathy were 11 times higher with iohexol than with iodixanol. All 6 incidents of acute renal failure occurred with iohexol; 2 resulted in death, 1 in persistent renal failure.

Comment: In diabetes patients with renal dysfunction undergoing mostly coronary angiography, less nephrotoxicity occurred with the iso-osmolar contrast agent iodixanol than with the somewhat higher-osmolarity agent iohexol. For both agents, contrast volumes were high; use of less contrast might have diminished the difference in nephrotoxicity between the 2 groups. Acetylcysteine, which has been shown in some studies to reduce nephrotoxicity (Journal Watch Cardiology Mar 7 2003), was used in only a few patients in this study and did not affect the findings. High-risk patients undergoing angiography should receive intravenous hydration and a minimal volume of contrast; these patients may benefit further from acetylcysteine and an iso-osmolar contrast agent.

— Howard C. Herrmann, MD

Published in Journal Watch Cardiology March 7, 2003

Citation(s):

Aspelin P et al. for the NEPHRIC Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003 Feb 6; 348:491-9.

Sandler CM. Contrast-agent-induced acute renal dysfunction -- Is iodixanol the answer? N Engl J Med 2003 Feb 6; 348:551-3.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2003. Massachusetts Medical Society. All rights reserved.